CU24188B1 - Composición vacunal contra el virus dengue - Google Patents

Composición vacunal contra el virus dengue

Info

Publication number
CU24188B1
CU24188B1 CUP2012000179A CU20120179A CU24188B1 CU 24188 B1 CU24188 B1 CU 24188B1 CU P2012000179 A CUP2012000179 A CU P2012000179A CU 20120179 A CU20120179 A CU 20120179A CU 24188 B1 CU24188 B1 CU 24188B1
Authority
CU
Cuba
Prior art keywords
seq
compositions
vaccine composition
oligonucleotide identified
immune response
Prior art date
Application number
CUP2012000179A
Other languages
English (en)
Other versions
CU20120179A7 (es
Inventor
Cruz Lisset Hermida
González Lázaro Gil
Oliva Alienys Izquierdo
López Ernesto Marcos
Portal Edith Suzarte
Nieto Gerardo Enrique Guillén
Tirado María Guadalupe Guzmán
Prado Iris Valdés
Vázquez Laura Lazo
Arechavaleta Angélica De La Caridad García
Vera Mayling Alvarez
Velazco Jorge Castro
Fernández Lázaro López
Bartutis Rosa Liset Ramírez
Fuentes Yusleidi De La Caridad Pérez
Guevara Olga Lidia Pérez
Fernández Yaremy Romero
Original Assignee
Ct De Ingeniería Genética Y Biotecnología
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct De Ingeniería Genética Y Biotecnología filed Critical Ct De Ingeniería Genética Y Biotecnología
Priority to CUP2012000179A priority Critical patent/CU24188B1/es
Priority to BR112015015138-8A priority patent/BR112015015138B1/pt
Priority to CA2894134A priority patent/CA2894134C/en
Priority to MYPI2015702127A priority patent/MY190698A/en
Priority to US14/655,227 priority patent/US9463235B2/en
Priority to SG11201505170WA priority patent/SG11201505170WA/en
Priority to JP2015549988A priority patent/JP6333290B2/ja
Priority to MX2015008482A priority patent/MX367424B/es
Priority to CN201380068237.7A priority patent/CN104936616B/zh
Priority to PCT/CU2013/000008 priority patent/WO2014101903A1/es
Priority to AU2013369626A priority patent/AU2013369626B2/en
Priority to HK15110603.1A priority patent/HK1209647B/xx
Priority to ES13823919T priority patent/ES2721921T3/es
Priority to EP13823919.9A priority patent/EP2939691B1/en
Priority to KR1020157015888A priority patent/KR102203759B1/ko
Priority to ARP130104975A priority patent/AR094238A1/es
Publication of CU20120179A7 publication Critical patent/CU20120179A7/es
Priority to PH12015501446A priority patent/PH12015501446B1/en
Publication of CU24188B1 publication Critical patent/CU24188B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee composiciones vacunales que comprenden al menos un antígeno basado en la proteína de la cápsida del virus dengue(VD) y el oligonucleótido identificado como SEQ ID NO. 1. La composición vacunal que comprende una proteína de fusión formada por la cápsida del VD2 y el dominio III de la proteína de la envoltura del mismo serotipo, agregada con el oligonucleótido identificado como SEQ ID NO. 1,genera los mayores niveles de respuesta inmune celular y protección en ratones, al compararla con la generada por formulaciones del mismo antígeno agregado con oligonucleótidos de potencial de capacidad adyuvante,reportados en la literatura.La efectividad de las composiciones que comprenden el oligonucleótido identificado como SEQ ID NO.1 se demostró, además, en primates no humanos.Las composiciones de la invención pueden ser monovalentes,bivalentes y tetravalentes, y se combinan en diferentes regímenes de inmunización para inducir respuesta inmune funcional frente a los cuatro serotipos virales.
CUP2012000179A 2012-12-27 2012-12-27 Composición vacunal contra el virus dengue CU24188B1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CUP2012000179A CU24188B1 (es) 2012-12-27 2012-12-27 Composición vacunal contra el virus dengue
PCT/CU2013/000008 WO2014101903A1 (es) 2012-12-27 2013-12-16 Composicion vacunal contra el virus dengue
AU2013369626A AU2013369626B2 (en) 2012-12-27 2013-12-16 Dengue virus vaccine composition
MYPI2015702127A MY190698A (en) 2012-12-27 2013-12-16 Dengue virus vaccine composition
US14/655,227 US9463235B2 (en) 2012-12-27 2013-12-16 Dengue virus vaccine composition
SG11201505170WA SG11201505170WA (en) 2012-12-27 2013-12-16 Dengue virus vaccine composition
JP2015549988A JP6333290B2 (ja) 2012-12-27 2013-12-16 デングウイルスワクチン組成物
MX2015008482A MX367424B (es) 2012-12-27 2013-12-16 Composicion vacunal contra el virus dengue.
CN201380068237.7A CN104936616B (zh) 2012-12-27 2013-12-16 针对登革病毒的疫苗组合物
BR112015015138-8A BR112015015138B1 (pt) 2012-12-27 2013-12-16 Composição de vacina contra o vírus da dengue, ácido nucleico e uso dos mesmos
CA2894134A CA2894134C (en) 2012-12-27 2013-12-16 Dengue virus vaccine composition
HK15110603.1A HK1209647B (en) 2012-12-27 2013-12-16 Dengue virus vaccine composition
ES13823919T ES2721921T3 (es) 2012-12-27 2013-12-16 Composición de vacuna del virus del dengue
EP13823919.9A EP2939691B1 (en) 2012-12-27 2013-12-16 Dengue virus vaccine composition
KR1020157015888A KR102203759B1 (ko) 2012-12-27 2013-12-16 뎅기 바이러스 백신 조성물
ARP130104975A AR094238A1 (es) 2012-12-27 2013-12-20 Composicion vacunal contra el virus dengue
PH12015501446A PH12015501446B1 (en) 2012-12-27 2015-06-22 Dengue virus vaccine composition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CUP2012000179A CU24188B1 (es) 2012-12-27 2012-12-27 Composición vacunal contra el virus dengue

Publications (2)

Publication Number Publication Date
CU20120179A7 CU20120179A7 (es) 2014-08-28
CU24188B1 true CU24188B1 (es) 2016-07-29

Family

ID=49999644

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2012000179A CU24188B1 (es) 2012-12-27 2012-12-27 Composición vacunal contra el virus dengue

Country Status (16)

Country Link
US (1) US9463235B2 (es)
EP (1) EP2939691B1 (es)
JP (1) JP6333290B2 (es)
KR (1) KR102203759B1 (es)
CN (1) CN104936616B (es)
AR (1) AR094238A1 (es)
AU (1) AU2013369626B2 (es)
BR (1) BR112015015138B1 (es)
CA (1) CA2894134C (es)
CU (1) CU24188B1 (es)
ES (1) ES2721921T3 (es)
MX (1) MX367424B (es)
MY (1) MY190698A (es)
PH (1) PH12015501446B1 (es)
SG (1) SG11201505170WA (es)
WO (1) WO2014101903A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115089700B (zh) * 2022-05-25 2025-07-25 永州中古生物技术有限公司 一种抗β属冠状病毒的疫苗组合物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22683A1 (es) * 1997-01-15 2001-07-20 Inst De Medicina Tropical Pedro Kouri Epítopes de la proteína pre-m/m del virus del dengue, péptidos sintéticos, proteínas quiméricas y sus usos
CU23245A1 (es) * 2001-07-16 2007-10-17 Inst De Medicina Tropical Pedr CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
US7592171B2 (en) * 2003-02-20 2009-09-22 Centro Nacional De Investigaciones Cientificas (Cnic) Vibrio cholerae with improved biological safety features in freeze dried form
CU23578A1 (es) * 2005-09-16 2010-09-30 Ct Ingenieria Genetica Biotech Proteína de la cápsida del virus dengue inductora de respuesta protectora y composición vacunal
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
CU20080028A6 (es) * 2008-02-29 2011-02-24 Ct Ingenieria Genetica Biotech Compuestos químicos obtenidos in silico para la preparación de composiciones farmacéuticas para atenuar o inhibir la infección por virus dengue y otros flavivirus

Also Published As

Publication number Publication date
JP6333290B2 (ja) 2018-05-30
EP2939691A1 (en) 2015-11-04
CN104936616A (zh) 2015-09-23
CA2894134A1 (en) 2014-07-03
HK1209647A1 (en) 2016-04-08
AR094238A1 (es) 2015-07-22
US9463235B2 (en) 2016-10-11
PH12015501446B1 (en) 2019-06-28
KR20150100660A (ko) 2015-09-02
AU2013369626B2 (en) 2017-07-27
WO2014101903A1 (es) 2014-07-03
MY190698A (en) 2022-05-11
CN104936616B (zh) 2017-06-20
EP2939691B1 (en) 2019-02-20
CU20120179A7 (es) 2014-08-28
JP2016505004A (ja) 2016-02-18
MX2015008482A (es) 2015-09-23
BR112015015138B1 (pt) 2022-05-17
ES2721921T3 (es) 2019-08-06
MX367424B (es) 2019-08-21
US20150328304A1 (en) 2015-11-19
SG11201505170WA (en) 2015-08-28
KR102203759B1 (ko) 2021-01-18
PH12015501446A1 (en) 2015-09-14
CA2894134C (en) 2021-04-06
BR112015015138A2 (es) 2017-08-15

Similar Documents

Publication Publication Date Title
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
CY1118003T1 (el) Αναπτυξη συστατικων εμβολιου ιου δαγκειου
HRP20190876T1 (hr) Novi adjuvantirani pripravci
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
MX2010007461A (es) Nuevas vacunas contra multiples subtipos del virus del dengue.
PE20140646A1 (es) Vacuna de virus de dengue inactivado
NZ630869A (en) Compositions and methods for dengue virus chimeric constructs in vaccines
MX352478B (es) Proteina vp6 de la capside de norovirus y rotavirus para el uso como vacuna combinada.
EA201891460A1 (ru) Композиция дендритных клеток
AR080111A1 (es) Metodos y composiciones de inmunizacion
UY32274A (es) Pestivirus quimericos
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
MX2021015972A (es) Vacuna contra la fiebre aftosa.
CO6470882A2 (es) Composiciones y metodos para administración de vacunas contra virus del dengue.
CU20120057A7 (es) Composición vacunal contra el virus del dengue, kit y plásmido
PH12015502666A1 (en) Dengue virus vaccine compositions and methods of use thereof
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.
UY35418A (es) Vacuna que proporciona protección frente a diferentes Picornavirus humanos.
MX338052B (es) Vectores de parapoxvirus que contienen el antigeno del virus de la rabia.
CO6700818A2 (es) Vectores de parapoxvirus
CU24188B1 (es) Composición vacunal contra el virus dengue
UY32876A (es) Régimen de inmunización por sensibilización-refuerzo heteróloga
TH170668A (th) องค์ประกอบ และวิธีการสำหรับชุดโครงสร้างไคมีริกไวรัสเด็งกีในวัคซีน
TR201907091T4 (tr) Yeni adjuvan kompozisyonları.
AR080845A1 (es) Vectores para vacunas y metodos para potenciar respuestas inmunes

Legal Events

Date Code Title Description
FG Grant of patent